
JeniVision is an early clinical stage biopharmaceutical company that strives to discover & develop innovative therapies in ophthalmology. Our proprietary non-invasive ocular delivery pathway (NIODP) enables successful drug delivery to the retina with high bioavailability. We have candidates in preclinical and clinical stages to not only treat debilitating diseases such as glaucoma and dry eye, but also prevent most common vision loss diseases like ROP, myopia and AMD. We believe that our innovative, non-invasive treatment for dry AMD will not only improve patient’s vision, but also prevent these patients from developing blinding wet AMD disease. With our creativity and ingenuity, we hope to forge new pathways in medicine for the future.
Notification to all contacts of JeniVision Inc.
August 26, 2024
Dear all,
Please note that the service agreement associated with the mailboxes below have been terminated:
Do not open any attachments, discard and report to the above mentioned service providers, if you receive any emails from these mailboxes.
Pleases email info@jenivision.com or corporate@jenivision.com to communicate with JeniVision Inc.
Sincerely.
JeniVision Inc.
Copyright © 2023 Jenivision INC. - All Rights Reserved.
Powered by GoDaddy Website Builder